Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Price was the key driver for the period
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
Subscribe To Our Newsletter & Stay Updated
